• English
  • 中文繁体
  • 中文简体
Hi,
moomoo ID:NaN
Log Out

Download App

Log in to access Online Inquiry
Quotes
Detailed Quotes
Company Overview
Company ProfileCompany Executives
Financial Analysis
Main CompositionKey IndicatorsFinancial Statement
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Company Overview More
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
CEO： --
Market： NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > CRSP CRISPR Therapeutics > Detailed Quotes

CRSP CRISPR Therapeutics

54.760+0.400+0.74%
Close 05/18 20:00 ET
54.750-0.01-0.02%
Post Mkt Price 05/18 17:26 ET
High
56.270
Open
53.010
Turnover
70.83M
Low
52.850
Pre Close
54.360
Volume
1.29M
Market Cap
4.24B
P/E(TTM)
14.08
52wk High
169.760
Shares
77.46M
P/E(Static)
11.65
52wk Low
42.511
Float Cap
4.18B
Bid/Ask %
0.00%
Historical High
220.200
Shs Float
76.32M
Volume Ratio
0.71
Historical Low
11.630
Dividend TTM
--
Div Yield TTM
150
P/B
1.89
Dividend LFY
--
Div Yield LFY
273.92%
Turnover Ratio
1.69%
Amplitude
6.29%
Avg Price
54.831
Lot Size
1
Float Cap
4.18B
Bid/Ask %
0.00%
Historical High
220.200
Shs Float
76.32M
Volume Ratio
0.71
Historical Low
11.630
Dividend TTM
--
P/B
1.89
Dividend LFY
--
Turnover Ratio
1.69%
Amplitude
6.29%
Avg Price
54.831
Lot Size
1
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast

No Data

News

Comment

News

Announcement